Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
5-azacytidine
100%
Advanced Solid Tumors
100%
Anti-EGFR
16%
Antiproliferative Activity
16%
Clinical Activity
16%
Cohort Design
16%
Conjunctivitis
16%
Daily Dose
16%
Diarrhea
16%
Dose-limiting Toxicity
16%
Epidermal Growth Factor Receptor
16%
Epigenetic Therapy
16%
Erlotinib
100%
Head-and-neck Cancer
16%
Hematotoxicity
16%
Infusion Reaction
16%
Larynx Cancer
16%
Lung
33%
Lung Cancer
16%
Malignancy
16%
Maximum Tolerated Dose
33%
Median Progression-free Survival
16%
Monotherapy
16%
Nausea
16%
Neutropenic Infection
16%
Nonhematologic
16%
Ovarian Cancer
16%
Ovarian Diseases
16%
Partial Response
16%
Phase I Study
100%
Phase II Study
16%
Rash
16%
RECIST Criteria
16%
Recommended Dose
16%
Stable Disease
33%
Tumor Malignancy
100%
Tumor Suppressor Gene
16%
Wild-type Epidermal Growth Factor Receptor
16%
Pharmacology, Toxicology and Pharmaceutical Science
Azacitidine
100%
Diarrhea
16%
Disease
33%
Epidermal Growth Factor Receptor
50%
Erlotinib
100%
Head and Neck Cancer
16%
Infection
16%
Larynx Cancer
16%
Lung Cancer
16%
Maximum Tolerated Dose
33%
Monotherapy
16%
Nausea
16%
Ovary Cancer
16%
Progression Free Survival
16%
Rash
16%
Solid Malignant Neoplasm
100%
Tumor Suppressor Protein
16%